

Recent Posts
- Attralus Receives FDA and EMA Orphan Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of AL and ATTR Amyloidosis
- Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
- Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate
- Attralus Announces New Clinical Data in ATTR CM and AL With AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent
- Quantification of Left Ventricular Amyloid in AL and ATTR Amyloid Cardiomyopathy: A Pilot 124I-p5+14 (AT-01) PET/CT and Echocardiography Study
Recent Comments
No comments to show.